Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma. J of Skin 2021, 5 (1), s2. https://doi.org/10.25251/skin.5.supp.2.